Bayer (FRA:BAYN) received a €120.00 ($148.15) target price from equities researchers at UBS in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. UBS’s price objective indicates a potential upside of 32.82% from the company’s current price.
A number of other equities analysts have also weighed in on the stock. Barclays set a €100.00 ($123.46) target price on shares of Bayer and gave the stock a “sell” rating in a research note on Tuesday, December 12th. Goldman Sachs set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. set a €128.00 ($158.02) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Friday, December 29th. Citigroup reaffirmed a “buy” rating on shares of Bayer in a research note on Friday, February 16th. Finally, Nord/LB set a €102.00 ($125.93) price objective on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday, December 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of €118.23 ($145.96).
Bayer stock opened at €90.35 ($111.54) on Thursday. The firm has a market cap of $78,800.00 and a price-to-earnings ratio of 24.29. Bayer has a one year low of €91.58 ($113.06) and a one year high of €123.82 ($152.86).
ILLEGAL ACTIVITY NOTICE: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3295003/bayer-bayn-given-a-120-00-price-target-by-ubs-analysts.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.